The American Journal of Medicine
Volume 119, Issue 10, Supplement 1 , Pages 46-53 , October 2006

Clinical Course of Chronic Obstructive Pulmonary Disease: Review of Therapeutic Interventions

  • Antonio Anzueto, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Antonio Anzueto, MD, Audie L. Murphy Memorial Veterans Hospital, 7400 Merton Minter Boulevard, San Antonio, Texas 78229.

References 

  1. Celli BR , MacNee W . Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper . Eur Respir J . 2004;23:932–946
  2. Fletcher C , Peto R . The natural history of chronic airflow obstruction . BMJ . 1977;1:1645–1648
  3. Anthonisen NR , Wright EC , Hodgkin JE . Prognosis in chronic obstructive pulmonary disease . Am Rev Respir Dis . 1986;133:14–20
  4. Anthonisen NR , Connett JE , Murray RP . Smoking and lung function of Lung Health Study participants after 11 years . Am J Respir Crit Care Med . 2002;166:675–679
  5. Anthonisen NR , Skeans MA , Wise RA , Manfreda J , Kanner RE , Connett JE . The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial . Ann Intern Med . 2005;142:233–239
  6. Boyd G , Morice AH , Pounsford JC , Siebert M , Peslis N , Crawford C . An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) . Eur Respir J . 1997;10:815–821
  7. Bouros D , Kottakis J , Le Gros V , Overend T , Della Cioppa G , Siafakas N . Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV1 reversibility . Curr Med Res Opin . 2004;20:581–586
  8. Dougherty JA , Didur BL , Aboussouan LS . Long-acting inhaled beta 2-agonists for stable COPD . Ann Pharmacother . 2003;37:1247–1255
  9. Casaburi R , Mahler DA , Jones PW , et al.  A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease . Eur Respir J . 2002;19:217–224
  10. Vincken W , van Noord JA , Greefhorst AP , et al.  Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium . Eur Respir J . 2002;19:209–216 for the Dutch/Belgian Tiotropium Study Group
  11. Anzueto A , Tashkin D , Menjoge S , Kesten S . One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium . Pulm Pharmacol Ther . 2005;18:75–81
  12. Kesten S, Flanders J, Menjoge S, Serby C. Maintenance of bronchodilation following tiotropium in patients with mild, moderate and severe COPD in one-year placebo-controlled clinical trials [abstract]. Abstract book of the first World Congress of the International Primary Care Respiratory Group (IPCRG); June 7–9, 2002; Amsterdam, Netherlands. Aberdeen, Scotland: IPCRG, 2002:24
  13. Decramer M , Celli B , Tashkin DP , et al.  Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the Uplift Trial . COPD: Journal of Chronic Obstructive Pulmonary Disease . 2004;1:303–312
  14. British Thoracic Society Standards of Care Subcommittee on Pulmonary Rehabilitation . Pulmonary rehabilitation . Thorax . 2001;56:827–834
  15. American Thoracic Society . Pulmonary rehabilitation—1999: official statement of the American Thoracic Society . Am J Respir Crit Care Med . 1999;159:1666–1682
  16. Casaburi R , Kukafka D , Cooper CB , Witek TJ , Kesten S . Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD . Chest . 2005;127:809–817
  17. Mahler DA , Wire P , Horstman D , et al.  Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease . Am J Respir Crit Care Med . 2002;166:1084–1091
  18. Hanania NA , Darken P , Horstman D , et al.  The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD . Chest . 2003;124:834–843
  19. Calverley PM , Boonsawat W , Cseke Z , Zhong N , Peterson S , Olsson H . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease . Eur Respir J . 2003;22:912–919
  20. Szafranski W , Cukier A , Ramirez A , et al.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease . Eur Respir J . 2003;21:74–81 [published correction appears in Eur Respir J. 2003;21:912]
  21. Vestbo J . The TORCH (Towards a Revolution in COPD Health) survival study protocol . Eur Respir J . 2004;24:206–210
  22. Global Initiative for Chronic Obstructive Lung Disease (GOLD) . Global Initiative for Chronic Obstructive Lung Disease (Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease—Updated July 2004) . Bethesda, MD: US Dept of Health and Human Services, National Institutes of Health; 2005;
  23. Anzueto A , Kesten S . Effects of tiotropium in COPD patients only treated with prn albuterol [abstract] . Am J Respir Crit Care Med . 2004;169:A611
  24. Adams SG , Anzueto A , Briggs DD , Menjoge SS , Kesten S . Tiotropium in COPD patients not previously receiving maintenance respiratory medications . Respir Med . 2006;100:1495–1503
  25. Anzueto AR , Sense W , Yates J , Brown C , Knobil K . Efficacy of Advair Diskus 250/50 (fluticasone propionate/salmeterol) in patients previously naïve to COPD maintenance therapy [abstract] . Chest . 2004;126(suppl):808S

PII: S0002-9343(06)00928-4

doi: 10.1016/j.amjmed.2006.08.007

The American Journal of Medicine
Volume 119, Issue 10, Supplement 1 , Pages 46-53 , October 2006

Article Tools

* Image Usage & Resolution